This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 0% and 16.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -37.04% and 0.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Ideas feature highlights: ETFMG Alternative Harvest ETF and Cronos Group
by Zacks Equity Research
ETFMG Alternative Harvest ETF and Cronos Group have been highlighted in this Investment Ideas article.
Are Marijuana Stocks A 'Buy' Amid U.S. Decriminalization Bill?
by Bryan Hayes
If signed into law, it would remove marijuana from the Controlled Substances Act (CSA).
Cronos Group (CRON) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 0% and 7.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 0.88% and 0.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 3.75% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Has CoDiagnostics, Inc. (CODX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how CoDiagnostics, Inc. (CODX) and Cronos Group (CRON) have performed compared to their sector so far this year.
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ulta Beauty and Freshpet have been highlighted as Zacks Bull and Bear of the Day
Ride The Cannabis Legalization Wave With These 3 Stocks
by Tirthankar Chakraborty
Stocks like Cronos Group (CRON), Canopy Growth (CGC) and Innovative Industrial Properties (IIPR) are sure to benefit at present amid the cannabis legalization wave.
Analysts Estimate Cronos Group (CRON) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cronos Group (CRON) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -28.57% and -13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for August 4th
by Zacks Equity Research
ARRY, CRON, ESTC, LEVL and TME have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2021.
Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cannabis Giant Tilray (TLRY) Skyrocketed Today
by Madeleine Johnson
Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.
New Strong Sell Stocks for July 16th
by Zacks Equity Research
JAZZ, MRNS, TWO, NCMI, and CRON have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2021
Markets Close Flat, Await New Jobs Data
by Mark Vickery
Tomorrow brings us our first steady diet of useful economic data of the week, with both normal Thursday Initial Jobless Claims and ADP (ADP) private-sector payrolls.
Cronos (CRON) Moves 15.2% Higher: Will This Strength Last?
by Zacks Equity Research
Cronos (CRON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cronos Group (CRON) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -50.00% and -25.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN
by Kinjel Shah
Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.
New Strong Sell Stocks for May 3rd
by Zacks Equity Research
BIDU, CRON, FORM, LTC, and SUNW have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2021
Earnings Preview: Cronos Group (CRON) Q1 Earnings Expected to Decline
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Mar 1, 2021
by Zacks Equity Research
Companies in The News Are: CRON,PEG,SSP,BLDR
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -216.67% and 23.67%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q4 results.